🇺🇸 FDA
Patent

US 11465994

MGluR7 agonist compounds for treating mGluR7-regulated diseases, disorders, or conditions

granted A61KA61K31/353A61K31/397

Quick answer

US patent 11465994 (MGluR7 agonist compounds for treating mGluR7-regulated diseases, disorders, or conditions) held by Takeda Pharmaceutical Company Limited expires Mon Oct 06 2042 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Takeda Pharmaceutical Company Limited
Grant date
Tue Oct 11 2022 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Oct 06 2042 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
25
CPC classes
A61K, A61K31/353, A61K31/397, A61K31/4025, A61K31/4433